# Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

> **NCT04920838** · PHASE2,PHASE3 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 600 (estimated)

## Conditions studied

- Covid19
- Covid19 Drug Treatment
- Severe Acute Respiratory Syndrome Coronavirus 2
- SARS-CoV2 Infection

## Interventions

- **DRUG:** Nitazoxanide and Ciclésonide
- **DRUG:** Telmisartan 20Mg Oral Tablet
- **DRUG:** Paracetamol
- **DRUG:** Fluoxétine and Budésonide

## Key facts

- **NCT ID:** NCT04920838
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-12
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2023-01-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920838, "Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04920838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*